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ABSTRACT:	The	rpoB	gene	encodes	the	b	subunit	of	RNA	polymerase	holoenzyme	in	Mycobacterium	leprae	
(M.	 leprae).	 Missense	 mutations	 in	 the	 rpoB	 gene	 were	 identified	 as	 etiological	 factors	 for	rifampin	resistance	 in	 leprosy.	 In	 the	present	study,	we	 identified	mutations	corresponding	to	rifampin	resistance	in	relapsed	leprosy	cases	from	three	hospitals	in	southern	India	which	treat	leprosy	patients.	DNA	was	extracted	from	skin	biopsies	of	35	relapse/multi	drug	therapy	non-respondent	 leprosy	 cases,	 and	PCR	was	performed	 to	 amplify	 the	276bp	 rifampin	 resistance-determining	 region	 of	 the	 rpoB	 gene.	 PCR	 products	 were	 sequenced,	 and	 mutations	 were	identified	in	four	out	of	the	35	cases	at	codon	positions	D441Y,	D441V,	S437L	and	H476R.	The	structural	 and	 functional	 effects	 of	 these	 mutations	 were	 assessed	 in	 the	 context	 of	 three-dimensional	 comparative	 models	 of	 wild-type	 and	 mutant	 M.	 leprae	 RNA	 polymerase	
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holoenzyme	(RNAP),	based	on	the	recently	solved	crystal	structures	of	RNAP	of	Mycobacterium	
tuberculosis	containing	a	synthetic	nucleic	acid	scaffold	and	rifampin.	The	resistance	mutations	were	observed	to	alter	the	hydrogen-bonding	and	hydrophobic	interactions	of	rifampin	and	the	5’	 ribonucleotide	 of	 the	 growing	 RNA	 transcript.	 This	 study	 demonstrates	 that	 rifampin-resistant	strains	of	M.	leprae	among	leprosy	patients	in	southern	India	are	likely	to	arise	from	mutations	that	affect	the	drug-binding	site	and	stability	of	RNAP.	
KEY	WORDS:	Rifampin;	 RNA	 polymerase;	 Comparative	 modelling;	 Normal	 mode	 analysis;	 Elastic-network	contact	model;	Mycobacterium	leprae	
INTRODUCTION:	Leprosy,	 a	 chronic	 infectious	 disease,	 is	 caused	 by	 an	 obligate	 intracellular	 pathogen	 -	
Mycobacterium	 leprae	 (M.	 leprae),	 which	 shares	 extensive	 similarity	 with	 Mycobacterium	
tuberculosis	 (M.	 tuberculosis)	 in	proteomic	and	genomic	composition1.	 	The	prevalence	rate	of	the	disease	has	gradually	declined	from	21.1	cases	per	10	000	people	in	1983	to	0.2	cases	per	10	000	people	in	2015,	and	this	was	achieved	with	the	use	of	the	World	Health	Organization	(WHO)	regimen	 of	Multi-Drug	 Therapy	 (MDT)2.	 The	 annual	 new	 case	 detection	 rates	 (ANCDR)	were	reduced	 from	5.2	million	 in	1983	to	~287,000	 in	2005.	Over	 the	past	decade,	 the	ANCDR	has	remained	stable,	with	214,783	new	leprosy	cases	reported	globally	in	2016,	of	which	135,485	were	 reported	 from	 India	 alone2.	 Development	 of	 drug	 resistance	 for	 anti-leprosy	 drugs	was	first	declared	for	dapsone	in	1964,	rifampin	in	1976	and	ofloxacin	in	19963.	The	emergence	of	drug	resistance	poses	a	much	greater	threat	of	resurgence	due	to	the	lack	of	effective	alternative	treatments	 such	 as	 vaccines,	 combined	 with	 poor	 understanding	 of	 the	 patterns	 of	transmission4,5.		The	conventional	gold	standard	for	detection	of	drug	resistance	in	leprosy	uses	mouse	footpad	propagation	(MFP),	a	slow	and	technically	challenging	approach	of	limited	use,	with	many	labs	relying	only	on	clinical	and	molecular	methods6.	The	presence	of	point	mutations	within	genes	encoding	known	drug	 targets,	 such	 as	DNA	gyrase,	 the	β-subunit	 of	RNA	polymerase	 (RNAP)	and	dihydropteroate	 synthases,	 is	widely	 considered	as	 an	 important	molecular	 signature	 for	drug	resistance	 in	leprosy7.	However,	 this	can	lead	to	many	 false	positives,	and	cannot	help	 in	determining	the	magnitude	of	resistance.	It	is	therefore	important	to	correlate	these	methods	of	detection	with	clinical	outcomes	in	order	to	develop	confidence	in	identifying	drug	resistance	in	leprosy.		Rifampin	 (also	known	as	 rifampicin)	belongs	 to	 the	 rifamycin	 class	of	 bactericidal	 drugs	 that	attenuate	 bacterial	 transcription,	 especially	 of	Mycobacteriacea,	 by	 inhibiting	 the	 enzymatic	activity	of	 the	b-subunit	 of	RNAP	holoenzyme	 (containing	 the	 subunits	 (bb’a’a’’ws))	 through	
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steric	occlusion	of	the	5’-ribonucleotide	of	the	growing	RNA	chain8.	Missense	mutations	in	the	
rpoB	 gene	 are	known	to	 induce	 changes	 in	 amino	acids	 that	 line	 the	 rifampin-binding	pocket	leading	 to	 structural	 changes	 and	 phenotypic	 resistance	 to	 rifampin	 in	M.	 leprae9.	 Mutations	usually	occur	between	codon	positions	410-480,	known	as	the	rifampin-resistance-determining	region	 (RRDR)10.	 There	 are	 approximately	 40	 mutations	 within	 the	 RRDR	 that	 possess	moderate-to-strong	correlation	with	clinical	non-responsiveness	to	rifampin	in	MDT	11	and	have	been	proven	using	the	MFP	test	and	surrogate	genetic	experiments.	Currently,	drug-resistance	screening	is	performed	only	on	cases	that	do	not	respond	clinically	to	MDT	and/or	are	cases	of	leprosy	relapse.	Diagnosis	is	based	on	the	presence	or	absence	of	mutations	and	is	coupled	with	clinical	evidences12.	Hence	identifying	mutations	within	the	rpoB	gene	support	determination	of	resistance,	which	is	otherwise	dependent	to	a	large	extent	on	the	clinical	profile	of	the	relapsed	leprosy	patients.		In	the	absence	of	an	axenic	culture	medium	and	where	MFP	experiments	are	challenging,	 it	 is	 important	 to	 establish	 a	 system	 that	 enables	 clinicians	 and	 researchers	 to	understand	reliably	the	impact	of	these	point	mutations	on	structural	changes,	drug	binding	and	loss/gain	in	function	of	the	drug	target.	Harnessing	computational	resources	to	understand	the	impact	of	point	mutations	on	drug-target	interactions	has	emerged	as	a	promising	alternative	to	
in-vitro	experiments	and	demonstrated	substantial	agreement	with	the	available	experimental	evidence13–21.	 Previous	 studies	 aimed	 at	 understanding	 the	 structural	 consequences	 of	 point	mutations	 in	 the	 rpoB	 gene	 of	M.	 leprae	 were	 limited	 to	 models	 based	 on	 distantly	 related	homologues	used	as	templates	to	construct	them	22,23.		In	 the	 current	 study,	we	 have	 identified	 point	mutations	within	 the	 RRDR	 of	 rpoB	 in	 clinical	isolates	 from	 relapsed	 leprosy	 cases	 and	 non/poor	 respondents	 to	 MDT	 at	 three	 hospitals,	which	 are	 treating	 leprosy	 patients	 in	 southern	 India.	 To	 perform	more	 accurate	 analysis	 of	effects	of	these	mutations	on	structure	and	function	of	RNAP	of	M.	leprae,	comparative	models	of	RNAP	were	built	and	structural	insights	obtained	from	a	recently	published	crystal	structure	of	RNAP	from	M.	tuberculosis8,	which	was	solved	at	a	resolution	of	3.8	Å	and	shares	96%	sequence	identity	with	that	of	M.	 leprae.	This	structure	revealed	that	rifampin	binds	to	 the	b	 subunit	of	RNAP	close	to	the	5’-end	of	the	growing	RNA	transcript,	where	it	induces	a	steric	clash	with	the	5’-ribonucleotide	 when	 the	 transcript	 is	 extended	 by	 three	 nucleotides,	 rendering	 this	ribonucleotide	unpaired,	unstacked	and	rotated	by	approximately	~40°.	This	clash	destabilizes	the	growing	chain	and	halts	transcription.	The	molecular	structures	of	RNAP	of	M.	tuberculosis	were	 solved	 in	 complex	with	 a	 synthetic	nucleic	 acid	 scaffold,	which	 contains	 a	non-template	DNA	strand	passing	through	a	cleft	into	the	active	center	and	with	a	three-ribonucleotide	RNA	chain	complementary	to	the	template	DNA	strand.	The	nucleic	acid	scaffold	is	characterized	by	sequence	specific	elements	that	are	necessary	for	recognition	by	mycobacterial	RNAP.	However,	no	mutant	structures	have	been	crystallized	to	date	to	decipher	the	structural	changes	induced	by	substitution	mutations	on	the	rifampin	binding	site.	
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We	identified	the	occurrence	of	rifampicin	resistance	in	leprosy	from	three	different	hospitals	in	southern	 India.	 Comparative	 three-dimensional	 models	 of	 wild-type	 and	mutant	 RNAP	 of	M.	
leprae	were	generated	to	evaluate	the	structural	changes	that	occur	due	to	point	mutations	and	their	impact	on	rifampin	binding	and	stability	of	transcription	in	M.	leprae.	
RESULTS:	
Clinical	 findings	on	 follow-up:	 Clinical	and	demographic	 characteristics	 of	 the	 leprosy	 cases	enrolled	in	the	study,	were	mentioned	in	Table	I.	On	monitoring,	it	was	noted	that	all	the	cases	responded	to	a	second	complete	round	of	WHO	MDT	that	was	administered	for	12	months	after	the	 diagnosis	 of	 relapse.	 This	 response	 was	 determined	 by	 the	 absence	 of	 new	 lesions	 and	additional	nerve	 function	 impairment.	One	of	 the	possible	 reasons	 for	 this	 response	 could	be	due	to	the	compensating	bactericidal	and/or	bacteriostatic	effects	rendered	by	the	other	drugs	in	the	MDT,	dapsone	and	clofazimine.	We	have	previously	shown	that,	while	M.	leprae-containing	rifampin-resistant	 mutations	 D441Y	 and	 D441V	 were	 unaffected	 by	 rifampin	 treatment,	administration	of	the	WHO	MB	regimen	of	MDT	led	to	reduced	bacterial	 load24.	It	was	unclear	whether	the	relapse	in	leprosy	is	due	to	reinfection	or	presence	of	persisters	in	the	body	from	previous	exposure.	
Table	I:	Clinical	and	Demographic	Characteristics	of	the	Study	Subjects	
Si.	No.	 Characteristics	 Types	
Relapsed/MDT-Non-
Respondent	Leprosy	Cases	
Number	 %	
1	 Gender	 Male	 24	 68.57	Female	 11	 31.43	
2	 Age	
1	-	15	 0	 0.00	
16-30	 7	 20.00	
31-50	 14	 40.00	
>50	 14	 40.00	
3	 WHO		Classification	
PB	 0	 0.00	
MB	 35	 100.00	
4	 Ridley	Jopling	Classification	
Indeterminate	
(IND)	 0	 0.00	
TT	 0	 0.00	
BT	 5	 14.29	
BB	 2	 5.71	
BL	 4	 11.43	
LL	 24	 68.57	
5	
Current	
Bacteriological	Index	
(BI)	
Negative	 3	 8.57	
1	-	2	 7	 20.00	
2.25-4	 14	 40.00	
4.25-6	 11	 31.43	
6	 MDT	Duration	
12	Months	 18	 51.43	
24	Months	 10	 28.57	
>	24	Months	 7	 20.00	
7	 Clinical	Status	 Relapse	 13	 37.14	Non- 22	 62.86	
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Mutations	detected	in	rpoB	gene	in	relapse/non-respondent	leprosy	cases:	Mutations	were	detected	 in	 four	 out	 of	 the	 35	 relapse/non-respondent	 leprosy	 cases	 within	 the	 rifampin	resistance	determining	region	of	 the	rpoB	gene.	The	mutations	 identified	were	D441Y,	D441V,	S437L	 and	 H476R	 (Table	 II).	 Sequence	 chromatograms	 with	 mutated	 regions	 are	 shown	 in	Supplementary	Material	1.	
Table	II:	Clinical	Characteristics	of	the	Cases	with	Mutations	in	the	rpoB	Gene	
	
Rifampin	binding	in	M.	leprae	RNAP:	The	surface	representation	of	RNAP	holoenzyme	model	of	M.	 leprae	 along	 with	 the	 nucleic	 acid	 scaffold	 and	 molecular	 structure	 of	 rifampin	 were	depicted	in	Fig:1.	The	model	shows	that	rifampin	binds	to	the	b	subunit	of	RNAP	(Chain	C)	by	forming	five	hydrogen	bonds	with	the	sidechains	of	R454,	R465	and	N493,	and	the	mainchain	of	Q438	 and	 F439	 (Fig:2).	 Additionally,	 it	 also	 forms	 weak	 hydrogen,	 hydrophobic	 and	 p	interactions	 with	 the	 surrounding	 residue	 environment.	 The	 piperazine	moiety	 of	 rifampin25	induces	a	steric	clash	with	the	base	of	the	5’-ribonucleotide,	resulting	in	unstacking	and	loss	of	base	pairing	with	the	RNA	transcript	after	it	is	extended	to	three	nucleotides8.	As	the	activity	of	rifampin	relies	on	its	ability	to	induce	a	steric	clash	with	the	5’-ribonucleotide,	mutations	that	influence	 its	 orientation	 in	 the	binding	pocket	might	 lead	 to	 reduction	 in	 these	 steric	 clashes	thereby	leading	to	rifampin	resistance.	
Rifampin	binding	in	mutant	M.	leprae	RNAP:	
D441Y	and	D441V:	Aspartate	at	the	position	441	in	the	wild-type	complex	(Fig:3a)	is	located	within	 the	 rifampin	 binding	 pocket	 and	 forms	 several	 interactions	 with	 the	 surrounding	residues,	some	of	which	include	backbone	and	sidechain	hydrogen	bonds	with	S447,	R454	and	
Respondents	
8	
Duration	between	
initial	
disease/treatment	
episode	and	relapse	
0-3	Years	 23	 65.71	
4-10	Years	 7	 20.00	
>	10	Years	 5	 14.29	
Si.	
No.	 Lab	ID	 Age/Sex	 WHO/RJ	
Previous	
/Current	
BI	
Previous	
MDT	De-
tails	
Time	
duration	
before	
relapse	
Classification	 Mutation	in	rpoB	
1	 DRS009	 38/M	 MB/LL-Histoid	 3.5+/3+	 2	Years	MB	MDT	 8	Years	 Relapse	 H476R	2	 DRS019	 45/F	 MB/LL	 NA/5+	 2	Years	MB	MDT	 10	Years	 Relapse	 S437L	3	 DRS027	 58/M	 MB/LL	 5+/4+	 24	Pulses	of	MB	MDT		 6	Years	 Relapse	 D441Y	4	 DRS029	 62/M	 MB/LL	 6+/3.66+	 2	Years	MB	MDT	 5	Years	 Relapse	 D441V	
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N443,	a	carbonyl	 interaction	with	G448	and	proximal	hydrophobic	 interactions	with	rifampin,	and	H451.	The	sidechain	oxygen	atom	forms	two	weak	hydrogen	interactions	with	carbons	20	and	21	of	 the	rifampin,	which	may	stabilize	 the	binding	of	rifampin.	Mutation	D441Y	(Fig:3b)	induces	 changes	 in	 the	 binding	pocket	 by	 introducing	 an	 aromatic	 sidechain	 into	 the	 pocket,	which	 destabilizes	 hydrogen-bonding	 interactions	with	 rifampin.	 It	 forms	many	 hydrophobic	interactions	with	R613	and	rifampin.	It	also	forms	donor-p	and	carbon-p	interactions	with	R454	and	rifampicin	which	might	impact	the	shape	and	conformation	of	the	rifampin	binding	pocket.	The	 D441V	 (Fig:3c)	 mutation	 results	 in	 the	 loss	 of	 hydrogen	 bonds	 with	 the	 surrounding	residues	that	may	contribute	to	conformational	changes,	leading	to	resistance.		
S437L:	In	the	wild-type	complex,	S437	is	located	at	a	distance	of	4.03	Å	from	bound	rifampin	and	 is	 involved	 in	 a	 mainchain	 hydrogen	 bonding	 interactions	 with	 S434	 and	 G432,	 and	 a	sidechain	hydrogen	bond	with	R173	(Fig:4a).	The	residue	is	stabilized	by	various	proximal	polar	interactions,	 which	 might	 contribute	 to	 the	 structure	 of	 the	 rifampin-binding	 pocket.	 In	 the	mutant	state,	S437L	(Fig:4b)	forms	one	mainchain	hydrogen	bond	with	S434	and	introduces	an	aliphatic	leucine	sidechain	in	the	binding	pocket,	which	forms	several	hydrophobic	interactions	with	 surrounding	 residues.	 Hence,	 loss	 of	 hydrogen-bond	 interactions	 coupled	 with	 the	development	of	a	hydrophobic	environment	may	 impact	 the	orientation	of	 the	rifampin	 in	 the	binding	site	and	lead	to	resistance.	
H476R:	H476	 is	 comparatively	 far	 from	 the	drug-binding	site	but	 is	 present	on	 the	 loop	that	supports	the	alpha-helix	in	the	binding	pocket	(Fig:	5a).	It	 is	 located	at	17.70	Å	from	rifampin	and	has	 a	dense	network	of	 ionic,	 carbon-p	and	donor-p	 interactions	 that	 contribute	 towards	stability.	The	side	and	mainchains	of	H476	forms	three	hydrogen	bonding	interaction,	two	with	S478	 and	 one	 with	 H479.	 It	 also	 forms	 an	 ionic	 interaction	 with	 D369.	 H476	 and	 H372	 are	involved	in	edge-to-face	ring	interactions,	with	the	distance	between	the	centroids	being	5.5	Å	and	angle	between	the	planes	 is	77.8o.	There	are	also	donor-p	and	carbon-p	 interactions	with	the	backbone	of	H372.	The	mutation	H476R	would	 lead	 to	a	 loss	of	 these	 ring-ring	 and	 ring-atom	 interactions,	 which	might	 result	 in	 the	 alpha	 helix	moving	 towards	 the	 binding	 pocket	leading	to	resistance	through	an	allosteric	mechanism	(Fig:	5b).	
Conservation	of	mutating	residues	in	wild-type	RNAP	of	M.	leprae:	The	wild-type	residues	D441,	 S437	 and	 H476	 are	 well	 conserved	 across	 mycobacterial	 species.	 Multiple	 sequence	alignment	 (using	 MUSCLE-alignment	 tool26)	 of	 the	 b-subunit	 of	 RNAP	 from	 M.	 leprae,	 M.	
tuberculosis,	M.	abscessus,	M.	ulcerans	and	M.	kansasii	showed	that	all	the	above	three	residues	were	conserved	(Supplementary	Material	1).	We	also	used	ConSurf	server27	to	understand	the	degree	of	 evolutionary	 conservation	of	 each	of	 the	 residues	 in	 a	probabilistic	 framework	and	noted	that	the	scores	for	residues	in	rifampin	binding	pocket	to	be	less	than	zero	indicating	that	they	are	conserved	(normalized	conservation	scores	D441	=	-	0.804,	S437	=	-0.841	and	H476	=	
7 
 
0.805).	
	
Structural	 and	 Functional	 Consequences	 of	 rpoB	 Resistance	 Mutations:	We	 used	 three	different	sets	of	tools	to	understand	the	changes	in	stability	and	interactions	between	subunits	of	RNAP,	ligands	and	nucleic	acids	in	the	RNAP	complex.	The	impacts	of	mutations	on	thermal	stability	were	 determined	 using	 Site	 Directed	Mutator	 (SDM)14	which	 considers	mutations	 in	specific	residues	based	on	their	local	structural	environments	where	substitution	probabilities	are	 calculated	 from	 analysis	 of	 families	 of	 protein	 homologues.	 Later	 we	 used	 a	 machine	learning	 approach	 called	 mutation	 cut-off	 scanning	 matrix	 (mCSM)13,15	 that	 uses	 the	pharmacophore	properties	 of	 the	mutating	 residues	 and	 calculates	 the	 changes	 in	 stability	 of	protein-protein,	 protein-nucleic	 acid	 and	 protein-ligand	 interactions.	 Finally,	 we	 used,	 a	vibrational	 entropy	 and	 enthalpy-based	 approach	 (ENCoM	 and	 FoldX4)28,49	 to	 measure	 the	impact	 of	 mutations	 on	 the	 flexible	 conformations	 of	 RNAP.	 Prediction	 of	 stability	 of	 RNAP	complex	by	mCSM15	indicated	a	stabilizing	effect	for	mutations	D441Y	and	D441V	while	slightly	destabilizing	effect	for	S437L	and	H476R	(Table	III).	Both	the	D441Y	and	D441V	mutations	were	known	to	exert	strong	resistance	to	rifampin	in	leprosy	as	studied	by	experimental	approaches.	Enhanced	 stability	 of	 the	 RNAP	 complex	 in	 the	 presence	 of	 these	 mutations	 might	 sustain	bacterial	transcription	even	in	the	presence	of	rifampin.	This	was	also	supported	by	the	mCSM-lig	predictions	where	 all	 the	mutations	 in	 the	 current	 study	were	predicted	 to	destabilize	 the	RNAP-rifampin	 interactions.	 Additionally,	 with	 both	 the	 D441Y	 and	 D441V	 mutations,	 an	enhanced	stability	of	protein-nucleic	acid	interaction	was	noted	indicating	that	these	mutations	may	 sustain	 protein-DNA	 and	 protein–RNA	 interactions	 and	 subsequent	 transcription	 (Table	III).	Except	for	H476R,	all	the	other	mutations	lie	within	a	4	Å	distance	from	the	ligand	and	in	the	 rifampin	 binding	 pocket.	 With	 S437L,	 both	 the	 protein	 as	 well	 as	 the	 protein	 ligand	interactions	 were	 predicted	 to	 be	 destabilized	 by	 mCSM	 and	 mCSM-lig	 indicating	 that	 this	mutation	not	only	impacts	the	binding	of	rifampin	but	also	alters	the	function	of	the	b	subunit	of	RNAP	 in	 transcription.	 Although	 located	 away	 from	 the	 rifampin	 binding	 site,	 the	 H476R	mutation	was	predicted	to	destabilize	the	protein	and	its	interactions	with	ligand,	nucleic	acids	and	 the	 interface.	 It	 was	 noted	 that	 this	 residue	 lies	 at	 the	 interface	 between	 the	 b	 and	 b’	subunits	 of	 RNAP	 and	 mutation	 may	 destabilize	 the	 interface	 of	 the	 subunits	 with	 -1.171	kcal/mol	 of	 change	 in	 energy	 (measured	 using	 mCSM-ppi).	 ENCoM	 and	 FoldX4	 programs	predicted	destabilizing	 energy	 changes	 in	RNAP	 in	 the	presence	of	 all	 the	 four	mutations.	By	generating	 normal	 modes	 using	 the	 elastic	 network	 contact	 model	 and	 calculating	 the	vibrational	entropy	and	enthalpy	changes	in	the	system,	these	programs	were	used	to	estimate	the	 impact	 of	 mutations	 on	 thermodynamic	 properties	 of	 RNAP	 and	 potential	 effects	 on	conformational	flexibility.		
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It	 was	 noted	 that	 the	 mutations	 induced	 a	 mild	 stabilizing	 effect	 in	 the	 backbone	 hydrogen	bonding	(as	noted	by	changes	in	free	energies)	when	compared	to	those	of	sidechain	hydrogen	bonds,	which	are	destabilizing.	As	most	of	the	mutated	residues	lie	within	the	rifampin-binding	pocket	 and	 their	 sidechains	 interact	 with	 rifampin,	 the	 destabilizing	 sidechain	 hydrogen	bonding	energies	positively	correlate	with	the	destabilizing	effects	rendered	by	mCSM-lig	(Table	IV).	Entropic	changes	in	both	sidechains	and	mainchains	of	the	mutating	residues	are	predicted	to	have	destabilizing	effects.	
Table	III:	Effect	of	Mutations	on	Protein	Stability	and	Interactions	with	Ligand,	Nucleic	
acid	and	Other	Protein	Subunits		
	*	 	 Except	 for	 ENCoM	 &	 FoldX4,	 all	 the	 positive	 values	 indicate	 a	 stabilizing	 effect	 while	 the	negative	values	indicate	a	destabilizing	effect	of	the	mutations.		**	The	final	energy	change	is	calculated	as	the	sum	of	the	predictions	by	ENCoM	and	FoldX4	and	hence	a	∆∆G	of	>	0.5	kcal/mol	is	considered	as	a	destabilizing	mutation.		In	the	rifampin-bound	structure,	interactions	with	rifampin	were	stabilized	by	the	formation	of	backbone	hydrogen	bonds	with	the	residues	lining	the	binding	pocket.	We	noted	that	hydrogen	bonds	 at	 position	 D441	 and	 S437	 stabilized	 the	 ligand	 in	 the	 binding	 pocket.	 Similar	observations	were	made	in	earlier	studies	but	with	models	that	built	from	templates	with	low	identity	 (~40%)22,23.	 The	mutant	models	 indicated	 a	 decrease	 in	 hydrogen-bond	 interactions	
Impact	of	Mutations	on	Protein	Stability	and	Ligand	Interaction	
(𝛥𝛥G	in	kcal/mol)	*	
Prediction	Tools	 D441Y	 D441V	 S437L	 H476R	
mCSM	 0.042	 1.513	 -0.031	 -0.933	
mCSM-lig	 -0.147	 -0.204	 -0.268	 -0.516	
mCSM-NA	 5.990	 0.345	 -3.55	 -1.008	
mCSM-PPI	 -0.294	 0.155	 -0.555	 -1.171	
DUET	 0.002	 1.597	 0.190	 -0.956	
SDM2	 -0.710 0.330	 1.280	 -1.870 
ENCoM	&	FoldX4**	 2.020 1.210	 1.880	 2.110 
Interface	Residue	 No No	 No	 Yes 
Distance	from	the	Interface	 7.080	Å	 7.080	Å	 7.090	Å	 3.550	Å	
Distance	from	the	Ligand	 3.435	Å	 3.435	Å	 4.000	Å	 16.745	Å	
Distance	from	the	Nucleic	
Acids	 7.082	Å	 7.082	Å	 12.344	Å	 8.624	Å	
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coupled	by	loss	of	interactions	leading	to	a	decline	in	van	der	Waals	and	desolvation	energies,	and	changes	in	the	binding	patterns.		These	observations	were	noted	in	earlier	studies	where	an	
in-silico	 docked	 model	 of	 the	 RNAP	 b	 subunit	 and	 rifampin	 revealed	 energy	 changes	 and	variations	 in	hydrogen	bonding	 interactions	when	mutations	were	 introduced	 in	 amino	acids	that	line	the	drug	binding	site8.	Amino	acid	substitutions	not	only	impacted	the	hydrogen	bonds	between	rifampin	and	RNAP	but	also	affected	 the	orientation	of	rifampin	in	the	pocket	which	was	noted	through	changes	in	polar	and	hydrophobic	interactions	in	mutants.	
Table	IV:	Energy	Changes	Calculated	by	ENCoM	and	FoldX4	(∆∆G	Expressed	in	kcal/mol)				
PDB/Energy	Characteristic*	 D441Y	 D441V	 S437L	 H476R	Total	Energy	 2.0281	 1.2158	 1.8890	 2.1128	Backbone	Hbond	 -0.1296	 -0.2289	 0.2056	 -0.6232	Sidechain	Hbond	 1.8841	 1.7381	 0.4473	 1.9277	van	der	Waals	 -0.8316	 -0.1233	 -1.7983	 0.2350	Electrostatics	 0.4630	 0.8407	 0.02593	 -2.2988	Solvation	Polar	 -0.6892	 -0.8747	 0.7040	 0.7178	Solvation	Hydrophobic	 -1.3490	 -0.5395	 -3.9192	 0.7932	van	der	Waals	Clashes	 1.6205	 -0.3424	 5.1669	 0.0401	Entropy	Sidechain	 0.1666	 0.0596	 0.6761	 1.1173	Entropy	Mainchain	 0.8137	 0.7074	 0.1137	 0.2425	Torsional	Clash	 0.0549	 -0.0349	 0.2669	 0.0381	Backbone	Clash	 -0.1666	 0.0035	 0.3899	 0.0677	Helix	Dipole	 0.0158	 0.0028	 0.0000	 0.0361	Energy	Ionisation	 0.0091	 0.01098	 -0.0000	 -0.1129		*The	final	energy	change	is	calculated	as	the	sum	of	the	predictions	by	ENCoM	and	FoldX4	and	a	∆∆G	of	>	0.5	kcal/mol	is	considered	as	a	destabilizing	mutation.	
Impact	of	mutations	on	wild-type	and	mutant	RNAP	models	in	flexible	conformations:		To	understand	the	impact	of	point	mutations	on	various	flexible	conformations	of	the	b	subunit	of	RNAP,	we	applied	NMA	using	ENCoM28.	NMA	was	confined	to	the	b	subunit	of	RNAP,	and	a	set	of	3387	normal	modes	were	generated	for	each	of	the	wild-type	and	mutant	models	(considering	1129	residues	in	the	b	subunit).	The	distortion	in	backbone	RMSD	from	the	static	conformation	was	 noted	 at	 each	 normal	mode	 and	 compared	 between	wild-type	 and	mutant	models.	 The	predicted	geometric	variations	 in	the	C-alpha	backbone	RMSD	under	 the	 influence	of	 the	 first	1000	vibrational	normal	modes	(considering	 the	presence	of	mutant	residues	within	 the	 first	
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500	amino	acids	of	the	sequence)	are	shown	in	Fig:6a-d.	The	distortions	between	the	400-800	normal	modes	 indicate	 a	difference	between	wild-type	 and	mutant	models.	This	difference	 in	distortion	 of	 backbone	 RMSD	 of	 the	 protein	 in	 flexible	 conformations	 may	 impact	 rifampin	binding	and	the	ensuing	resistance.	
DISCUSSION:		Secondary	 resistance	 to	 rifampin	 in	 Indian	 leprosy	 patients	 has	 been	 reported	 from	 the	 year	200129.	 These	 studies	 were	 dependent	 to	 a	 large	 extent	 on	 clinical	 outcomes	 and	 MFP	experiments	 in	 the	 absence	 of	 axenic	 culture	 medium.	 Leprosy	 cases	 whose	 lesions	 and	 BI	remain	 stable	 without	 changes	 during	MDT	 and/or	 develop	 new	 lesions	 during	 therapy	 are	clinically	 suspected	 as	drug	 resistant.	On	 the	other	hand,	 cases	 that	are	 cured	 after	MDT	and	develop	new	signs	or	symptoms	post	treatment	are	categorized	as	relapse,	which	can	be	due	to	drug	 resistance	 or	 reinfection.	 A	 total	 of	 536	 relapse	 leprosy	 cases	were	 reported	 in	 India	 in	20162;	 however,	 only	 3-5%	 of	 these	 carry	mutations	 conferring	 rifampin	 resistance	 as	 noted	from	the	unpublished	data	collected	by	WHO	Sentinel	surveillance	study	on	Drug	Resistance	in	Leprosy11.	 There	 are	 recent	 reports	 of	 the	 emergence	 of	 primary	 resistance	 to	 rifampin	 in	leprosy30	based	on	the	observation	of	mutations	within	RRDR	in	new	cases;	however,	follow-up	is	needed	to	determine	the	clinical	outcomes	of	resistance	as	most	of	these	cases	may	respond	to	combinatorial	therapy	(MDT)	and	are	cured.			Four	 cases	 that	 were	 identified	 to	 be	 drug	 resistant	 in	 the	 current	 study,	 relapsed	 after	 an	average	 duration	 of	 approximately	 seven	 years	 from	 the	 first	 episode	 of	 the	 disease	 and	complete	 regimen	 of	MB	MDT.	 It	was	 noted	 that	 these	 cases	 demonstrate	 high	 bacillary	 load	with	 BI	 greater	 than	 2+	 and	 belong	 to	 lepromatous	 leprosy.	 Lepromatous	 leprosy	 (LL)	 is	characterized	 by	 high	 bacillary	 loads	 and	 low	 M.	 leprae	 specific	 cell-mediated	 immune	responses31	 in	 the	 host,	 increasing	 likelihood	 of	 the	 presence	 of	 bacterial	 persisters	 post-treatment	which	may	adopt	to	rifampin	by	inducing	point	mutations	with	the	RRDR.	Most	of	the	rifampicin-resistant	strains	of	M.	leprae	 that	are	proven	resistant	in	the	MFP	approach,	harbor	mutations	in	the	RRDR	of	M.	leprae	genome6.	There	is	no	definitive	test	to	differentiate	relapse	(due	 to	bacterial	persisters)	 from	reinfection	except	 for	recent	observations	 in	whole	genome	analysis4,	which	is	a	difficult	technique	to	perform	in	a	diagnostic	laboratory	setting	in	tropical	countries	that	are	endemic	to	leprosy.	 	It	 is	therefore	not	known	whether	the	four	cases	in	the	current	study	were	re-infected	with	the	drug-resistant	bacilli	or	possess	bacterial	persisters	that	turned	resistant	to	rifampin	by	inducing	mutations	over	time.			Due	 to	 the	 low	 level	 of	 concordance	 between	MFP,	 genetic	methods	 and	 clinical	 outcomes	 of	drug	resistance	in	leprosy,	use	of	computational	methods	to	understand	the	structural	effects	of	point	 mutations	 provide	 possible	 associations	 between	 genetic	 changes	 and	 concurrent	
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phenotypic	 outcomes.	 	 Mechanistic	 insights	 into	 rifampin	 resistance	 in	 leprosy	 are	 also	important	for	developing	new	therapeutic	strategies.	Surrogate	genetic	models	were	used	for	M.	
leprae	 to	 determine	 the	 magnitude	 of	 resistance	 to	 rifampin	 and	 understand	 functional	outcomes9.	 Mutation	 D441Y	 was	 reported	 in	 the	 year	 20017	 and	 was	 later	 proved	experimentally	to	cause	phenotypic	resistance	in	M.	smegmatis.	It	was	noted	that	the	MIC	values	have	 increased	 by	 32-fold	 in	 mutant	 strains	 indicating	 that	 the	 D441Y	 mutation	 can	 cause	strong	phenotypic	resistance	to	rifampin9.	Mutation	at	codon	position	437	was	reported	by	us	for	the	first	time	in	the	current	study.	A	very	close	substitution	at	the	adjacent	residue	position	436,	where	 leucine	 is	 replaced	by	 either	proline	or	 serine,	was	noted	 in	a	 few	 studies	 and	 is	known	 to	 cause	 phenotypic	 resistance	 to	 rifampin32.	 Similar	 mutations	 were	 also	 known	 to	confer	 resistance	 to	 rifampin	 in	 other	 mycobacteria.	 The	 mutation	 at	 position	 476	 also	conferred	rifampin	resistance	in	M.	leprae	isolates	from	Thailand33.		Structural	 characterization	 of	 RNAP	 of	 M.	 tuberculosis	 revealed	 that	 amino	 acids	 that	 are	spanning	positions	410	to	480	(residues	were	numbered	according	to	the	b	subunit	of	RNAP)	line	 the	 active	 catalytic	 core	 of	 the	 enzyme.	 The	b	 subunit	 of	RNAP	 of	M.	 leprae	 resembles	 a	“crab-claw”	with	a	cleft	that	is	approximately	30	Å	deep.	The	active	site	where	rifampin	binds	lies	 in	 the	 central	 part	 of	 the	 cleft	 facing	 the	 anterior	 arm.	 mCSM-lig	 predictions	 support	 a	destabilizing	 effect	 on	 the	 protein-ligand	 interactions	 in	 all	 the	 mutations	 identified	 in	 the	current	study	as	they	lie	within	or	close	to	the	active	site.		This	program	uses	an	in-silico	model	that	 relies	 on	 interatomic	 distance	 graphs,	 pharmacophore	 information	 of	 the	 residues	 and	available	 experimental	 data	 on	 mutations,	 and	 predictions	 made	 by	 this	 machine	 learning	program	correlate	with	experimental	outcomes	of	mutations	D441Y	and	D441V.	Due	to	the	lack	of	 a	 quick	 and	 robust	 experimental	 model	 to	 determine	 the	 effect	 of	 mutations	 on	 drug	resistance	 in	 leprosy,	 use	 of	 predictive	 tools	 like	 mCSM-lig	 provides	 important	 preliminary	information	on	 the	 changes	 in	binding	affinity	between	drug	 targets	 and	their	 corresponding	ligands.		Wild-type	RNAP	with	 a	 flexible	 conformation	may	 facilitate	proper	orientation	of	 rifampin	 in	the	active	site	enabling	the	piperazine	ring	to	induce	steric	clash	on	the	5’-ribonucleotide	of	the	RNA	 transcript	 and	 repress	 transcription.	 Changes	 in	 the	 conformations	 that	 are	 accessible	(noted	 as	 RMSD	 distortions	 at	 normal	 modes)	 in	 the	 mutant	 models	 suggest	 that	 they	 may	impact	rifampin	binding.	This	generates	structural	evidence	that	these	point	mutations	impact	not	 only	 the	 stability	 but	 also	 the	 dynamics	 of	 the	 RNAP	 system,	 leading	 to	 phenotypic	resistance	to	rifampin.		The	atomic	coordinates	for	RNAP	of	M.	leprae	were	predicted	from	the	homologous	structure	in	
M.	tuberculosis	by	comparative	modelling	considering	the	spatial	restraints.	The	residues	in	the	
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rifampin	binding	pocket	 of	 the	b	 subunit	 between	positions	400	and	500	are	well	 conserved	across	mycobacterial	 species.	 All	 the	mutated	 residues	 in	 the	 current	 study	were	 conserved	between	RNAP	of	M.	leprae	and	its	homologue	in	M.	tuberculosis	as	identified	from	the	multiple	sequence	alignments.	Although	the	model	was	built	from	M.	tuberculosis	RNAP	structure	with	a	resolution	of	3.8	Å,	it	was	the	best	template	available	with	high	sequence	identity	to	that	of	M.	
leprae.	 Available	 knowledge	 of	 the	 structures	 of	 other	 bacterial	 RNAPs	 lends	 additional	credibility	as	to	the	reliability	of	the	structure,	particularly	in	the	vicinity	of	the	rifampin	binding	site	which	is	highly	conserved	across	mycobacterial	species.	The	program	Andante42	considers	conserved	c-angle	conservation	rules	from	structurally	aligned	families	of	homologous	proteins	when	 building	 the	mutant	models	 so	 that	 the	 entire	 side-chain	 conformations	 are	 accurately	borrowed,	 and	 steric	 clashes	 are	 avoided	 in	 the	models.	 The	 reliability	 of	modest	 resolution	structures	is	enhanced	by	the	use	of	the	stereochemical	restraints	in	refinement,	as	is	now	done	routinely	and	powerfully	in	modern	program	suites	such	as	PHENIX34.	As	M.	leprae	is	an	obligate	pathogen	and	cannot	be	propagated	on	an	axenic	culture	medium,	it	is	 exceptionally	 challenging	 to	 reconstitute	 the	 whole	 complex	 of	 RNAP	 and	 ascertain	 the	structural	changes	experimentally,	for	each	of	the	mutants.	Most	of	the	computational	analysis	was	 performed	 based	 on	 the	 structural	 information	 from	 the	 model	 built	 from	 RNAP	 of	M.	
tuberculosis.	While	the	RNAP	model	of	M.	leprae	is	highly	identical	to	the	experimental	structure	of	that	of	M.	tuberculosis,	most	of	the	residues	in	the	rifampin	binding	region	of	the	b	subunit	of	RNAP	 are	 well	 conserved	 across	 mycobacterial	 species	 and	 retain	 similar	 interatomic	interactions	 with	 rifampin. Mutations	 at	 residue	 positions	 D441	 and	 S437	 were	 noted	 in	rifampin	 resistant	 and	multidrug	 resistant	 strains	 of	M.	 tuberculosis35,36	 and	 these	mutations	confer	 phenotypic	 resistance	 to	 rifampin.	 Lack	 of	 experimental	 validation	 of	 changes	 in	rifampin-RNAP	 interactions	 upon	mutations	 becomes	 a	 limiting	 factor	 for	 the	 current	 study.	Although	the	mutations	correlated	with	the	clinical	outcomes	of	rifampin	resistance	in	leprosy	(as	 noted	 by	 leprosy	 relapse),	 it	 is	 important	 to	 experimentally	 validate	thermodynamic/structural	changes	in	proteins	upon	mutations	to	comprehensively	understand	the	mechanism	of	drug	resistance.	The	predicted	conformational	changes	provide	preliminary	insights	into	the	future	development	of	a	robust	system	involving	a	surrogate	model	as	that	of	
M.	 smegmatis,	 to	 study	 the	 effect	 of	 the	 mutations	 on	 MICs9	 and	 possibly	 conformational	changes	in	RNAP	if	the	whole	complex	can	be	purified/reconstituted	from	M.	leprae	with	nucleic	acids	 and	 rifampin.	 A	 more	 tractable	 approach	 based	 on	 currently	 available	 Mycobacterial	RNAPs	that	have	been	crystallized	could	be	to	transplant	the	amino	acid	residues	from	the	M.	
leprae	rifampicin-binding	region	onto	either	M.	tuberculosis	or	M.	smegmatis	RNAPs	and	analyse	the	 structural	 implications	 of	 the	 mutations	 by	 either	 crystallography	 or	 cryo-electron	microscopy.	
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In	conclusion,	we	have	modelled	 for	the	 first	 time,	a	RNAP	holoenzyme	of	M.	 leprae	using	 the	crystal	structure	of	M.	 tuberculosis	RNAP	as	a	 template.	Our	experimental	results	 indicate	 the	presence	of	 rpoB	mutant	 strains	of	M.	 leprae	 in	 southern	 Indian	 leprosy	patients	and	 in-silico	modelling	provides	mechanistic	insights	into	the	impacts	of	these	mutations	on	the	binding	of	rifampin	 to	RNAP	 in	M.	 leprae.	 Three	of	 the	mutations	 that	 are	 reported	 in	 the	 current	 study	were	identified	earlier	by	other	groups	and	are	known	to	exert	strong	to	moderate	resistance	to	rifampin.	The	 loss	of	interactions	predicted	 in-silico	 in	 terms	of	energy	changes	and	hydrogen	bond	 interactions	 demonstrate	 concordance	 with	 the	 in	 vitro	 experiments	 that	 indicated	resistance.	 Similar	 observations	 were	 noted	 in	 one	 of	 our	 studies	 on	 dapsone	 resistance	 in	leprosy37.	Hence	this	computational	approach	can	further	be	used	to	study	novel	mutations	to	procure	preliminary	information	on	their	impacts	on	structure	and	function	of	drug	targets	and	the	resulting	phenotypic	drug	resistance	in	leprosy.	
METHODS:	
Study	Sample:	A	total	of	35	multi-bacillary	(MB)	leprosy	cases,	which	were	clinically	diagnosed	as	relapsed	or	non/poor	respondents	to	MDT,	was	enrolled	in	the	study.	These	were	diagnosed	at	 the	 dermatology	 out-patient	 departments	 of	 “Schieffelin	 Institute	 of	 Health-Research	 &	Leprosy	Centre	(SIH-R&LC)”	Karigiri	-	Tamil	Nadu,	“Father	Muller	Foundation	Medical	College	–	Mangalore,	Karnataka	and	“Government	Medical	College	–	Trivandrum	in	Kerala.	A	part	of	the	excisional	skin	biopsy	from	the	site	of	active	skin	lesion	collected	for	routine	histopathological	examination	was	 sent	 to	 the	Molecular	 Biology	Laboratory	 at	 SIH-R&LC	Karigiri	 for	 PCR	and	DNA	 sequencing	 to	 screen	 for	 mutations.	 All	 the	 procedures	 were	 conducted	 following	 the	guidelines	 of	 the	 ethical	 committee	 of	 SIH-R&LC	 –	 Karigiri	 -	 Tamil	 Nadu,	 India,	 and	 ethical	standards	 as	 laid	 down	 in	 the	 1964	 Declaration	 of	 Helsinki	 and	 its	 later	 amendments	 or	comparable	 ethical	 standards.	 Informed	 and	 written	 consent	 for	 participation	 was	 obtained	from	 all	 the	 participants	 involved	 the	 study	 following	 the	 ethical	 guidelines	 of	 SIH-R&LC	 –	Karigiri	-	Tamil	Nadu,	India	before	enrolling	in	the	study.	All	the	experiments	conducted	in	the	study	were	approved	by	the	institutional	ethical	committee	of	SIH-R&LC,	Karigiri.	Demographic	and	 clinical	 characteristics	 of	 the	 sample	 are	 represented	 in	 Table	 I.	 According	 to	 the	WHO,	relapse	 in	 leprosy	 is	 defined	 as	 “the	 multiplication	 of	 M.	 leprae,	 suspected	 by	 the	 marked	increase	(at	least	2+	over	the	previous	value)	in	the	bacteriological	index	(BI)	at	any	single	site,	usually	with	evidence	of	clinical	deterioration	(new	skin	patches	or	nodules	and/or	new	nerve	damage)”38.	
DNA	 Extraction:	 DNA	was	 extracted	 from	 skin	 biopsies	 using	 the	 previously	 described	 lysis	protocol39.	Briefly,	25	mg	of	tissue	was	thoroughly	manually	homogenized,	mixed	with	1	ml	of	1X	phosphate-buffered	saline	(PBS),	centrifuged	at	8600g	for	10	min	at	4°C	and	the	pellet	dried	for	1	 hr.	 at	 50°C.	 Later,	 200	 µl	 of	 lysis	 buffer	 containing	 100	 mM	 Tris	 at	 pH	 8.5,	 1	 mg/ml	 of	
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proteinase	K	 and	0.05%	Tween	20	was	 added	 to	 the	homogenate,	 vortexed	and	 incubated	 at	60°C	in	a	water	bath	(Polystat	–	Cole	Parmer	Inc.)	for	16	hrs.	Post	incubation,	proteinase	K	was	heat	inactivated	at	95°C	for	15	min.	The	lysate	was	cooled	to	room	temperature,	and	DNA	was	isolated	by	phenol	chloroform	extraction.	DNeasy	Kit	(Cat	No:	69504,	Qiagen	Inc.	Netherlands)	was	used	in	samples	where	the	tissue	content	was	low.	
PCR	 and	 Detection	 of	Mutations	within	 the	 rpoB	 Gene:	 PCR	was	 performed	 as	 described	earlier22.	Briefly,	a	20	μl	PCR	reaction	mix	was	prepared	using	10	μl	of	Hot	Start	PCR	Master	Mix	(Qiagen	 Inc.	 Netherlands),	 2	 μl	 of	 Q	 solution	 (Qiagen	 Inc.	 Netherlands),	 ≈2μg	 of	 DNA	 and	forward	 &	 reverse	 primers	 for	 rpoB	 gene,	 each	 at	 0.25	 μM	 concentration.	 The	 mixture	 was	cycled	37	times	on	a	thermal	cycler	at	94oC	for	1	min,	60oC	for	1	min	and	70oC	for	1	min	which	was	preceded	by	initial	denaturation	at	95oC	for	15	min	and	terminated	by	a	final	extension	at	72oC	for	10	min.	3-5	μl	of	the	amplified	PCR	product	was	electrophoresed	on	2%	Agarose	gel	for	detection	 of	 276bp	 rpoB	 amplicons.	 The	 presence	 of	mutations	within	 the	 amplified	 product	was	confirmed	by	DNA	sequencing	through	a	commercial	agency	–	Scigenom	Pvt.	Ltd.	at	Cochin	in	 Kerala,	 India.	 Sequence	 data	was	 analyzed	 using	MEGA	Version-7	 (Molecular	 Evolutionary	Genetics	Analysis)	and	Sequencher	V.	5.4.6	The	residue	positions	and	mutations	were	numbered	based	 on	 the	 reference	 strain	 (BR4923)	 of	 M.	 leprae	 with	 Genbank	 accession	 number:	NC_002677.1.	
Comparative	Modelling	of	RNAP	of	M.	leprae:	Comparative	models	for	RNAP	holoenzyme	of	M.	leprae	were	generated	using	templates	from	M.	
tuberculosis	 1(PDB	ID:5UH5	(96%	identity,	3.8	Å	resolution),	which	contain	RNAP	and	nucleic	acid	 scaffold	 with	 DNA	 and	 three	 nucleotides	 of	 RNA	 complementary	 to	 the	 template	 DNA	strand	and	PDB	ID:	5UHC	(96%	identity,	4.0	Å	resolution)	containing	all	the	elements	similar	to	5UH5	and	rifampin).	Molecular	modelling	was	performed	using	Modeller	9.1740.	We	modelled	all	the	 subunits	 of	 RNAP	 of	M.	 leprae	 (Fig-1)	 and	 assembled	 them	 together	 with	 the	 synthetic	nucleic	acid	scaffold	containing	a	strand	of	non-template	DNA,	template	DNA	and	a	3	nt	stretch	of	RNA	with	and	without	rifampin	using	UCSF	Chimera41.	The	modelled	structures	exhibited	a	root	mean	 square	 deviation	 (RMSD)	 of	 0.304	 Å	 with	 PDB	 ID:	 5UH5	 (Crystal	 structure	 of	M.	
tuberculosis	transcription	initiation	complex	containing	3	nt	of	RNA)	and	0.203	Å	with	PDB	ID:	5UHC	(Crystal	structure	of	M.	tuberculosis	transcription	initiation	complex	containing	3	nt	RNA	in	complex	with	rifampin).		The	mutant	models	were	generated	using	ANDANTE42,	a	program	that	uses	c	angle	conservation	rules	 for	 the	 sidechains	 surpassing	 the	 need	 to	 screen	 a	 large	 rotamer	 library	 for	 proper	orientation	 of	 side	 chains	 in	 comparative	modelling.	 Fold	 assessments	were	 performed	 using	NDOPE43	 and	 GA34144	 methods.	 Additionally,	 the	 models	 were	 analyzed	 for	 quality	 using	Rampage45,	and	Molprobity46.	Interatomic	interactions	were	analyzed	using	in-house	developed	
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tools,	Arpeggio47	and	 Intermezzo	 (Bernardo	O.M	and	Blundell	T.L..,	 unpublished).	The	models	were	built	with	96%	identity	and	98%	coverage.	Assessment	on	Rampage	indicates	96.6%	in	the	favored	regions	and	3.1%	in	the	allowed	regions.	
Mutation	Analysis:	Structural	and	thermodynamic	changes	that	occur	due	to	point	mutations	in	RNAP	were	 analyzed	using	 in-house	developed	 tools	namely	mCSM15	 and	SDM14.	Mutation	cutoff	 scanning	 matrix	 (mCSM)	 relies	 on	 graph-based	 signatures.	 The	 signatures	 encode	interatomic	 distance	 patterns	 that	 define	 the	 residue	 environment.	 These	 together	 with	pharmacophore	 characteristics	 are	 used	 to	 train	 predictive	 models.	 This	 approach	 helped	understanding	 the	 impact	 of	 mutations	 on	 protein	 stability	 (mCSM)15,	 protein-ligand	interactions	 (mCSM-lig)13,	 protein-protein	 interfaces	 (mCSM-ppi)15	 and	 protein-nucleic	interactions	 (mCSM-NA)48.	 We	 also	 used	 other	 in-house	 tools	 such	 as	 Site	 Directed	 Mutator	(SDM2)14,	 which	 predicts	 thermodynamic	 changes	 upon	 mutations	 using	 structural	environment-dependent	amino	acid	substitution	tables	and	DUET16,	which	is	a	combination	of	mCSM	and	SDM.		
Normal	 Mode	 Analysis:	 Normal	 mode	 analysis	 (NMA)	 was	 performed	 to	 determine	 the	covariance	of	alpha	carbon	atoms	in	various	normal	modes	in	the	wild-type	and	mutant	RNAP	models.	The	 impact	 of	 point	mutations	on	protein	 stability	 and	dynamics	was	analyzed	using	Elastic	 Network	 Contact	 Model	 (ENCoM)28,	 which	 uses	 a	 coarse-grained	 NMA	 to	 improve	conformational	space	sampling.	It	accounts	for	the	nature	of	the	amino	acids	and	introduces	a	pairwise	atom	type	term	proportional	to	the	surface	area	that	is	in	contact	with	the	heavy	atoms	in	the	potential.	It	predicts	conformational	changes	and	remodels	the	protein	in	various	flexible	conformations	using	Modeller	9.1740	while	considering	each	conformational	state	as	a	template.	This	method	allows	for	proper	placement	of	bond	angles	and	spatial	constraints	for	each	model	in	a	conformational	ensemble.	Normal	modes	were	generated	for	wild-type	and	mutant	models,	and	 an	 RMSD	 (root	mean	 square	 deviation)	 grid	was	 built	 from	 the	 eigenvectors	 where	 the	backbone	 RMSD	 fluctuated	 within	 a	 threshold	 amplitude	 of	 2	 Å.	 The	 1129	 (N)	 amino	 acids	corresponding	 to	 the	b	 subunit	 of	 RNAP	were	 used	 to	 produce	 a	matrix	 of	 3N	 x	3N.	 Various	interaction	energies	of	the	RNAP	complex	were	determined	using	FoldX449	with	the	R	statistical	package.	R	scripts	 from	ENCoM50	were	used	 to	calculate	changes	 in	RMSD	 in	different	normal	modes.	
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Figure	Legends:		Figure	1:	[a]	RNAP	holoenzyme	of	M.	leprae	in	complex	with	synthetic	nucleic	acid	scaffold	and	rifampin.	 [b]	 Heterocyclic	 structure	 of	 rifampin	 (orange)	 with	 the	 piperazine	 moiety	 and	naphthoquinone	core	that	is	spanned	by	an	aliphatic	chain.			Figure	2:	 [a]	 Interatomic	 interactions	of	 rifampin	(orange)	with	 the	b	 subunit	of	RNAP.	All	 the	interacting	 and	 proximal	 residues	 were	 depicted.	 The	 black	 dashed	 lines	 indicate	 hydrogen	bonding	 interactions	and	green	dashed	 lines	 indicate	hydrophobic	 interactions.	 	 [b]	Hydrogen	bonds	(black	dashed	lines)	between	rifampin	and	sidechains	of	R454,	R465	and	N493,	and	the	mainchain	of	Q438	and	F439.		Figure	 3:	 [a]	 Interatomic	 interactions	 of	 D441	 (green)	with	 the	 residue	 environment	 in	wild-type	 complex.	D441,	 located	at	 a	distance	of	 3.43	Å	 from	 rifampin	 (orange),	makes	hydrogen	bonds	with	side	chains	of	S447,	R454	and	N443	(black	dashed	lines),	a	carbonyl	interaction	with	G448	(red	dashed	line)	and	proximal	hydrophobic	interactions	with	rifampin,	and	H451	(green	dashed	 lines).	 [b]	 Mutant	 Y441	 interactions	 with	 the	 residue	 environment.	 Y441	 makes	hydrogen	bonds	(black	dashed	lines),	hydrophobic	 interactions	(green	dashed	lines),	carbon-p	interactions	(grey	dashed	lines)	and	donor-p		interactions	(blue	dashed	lines).	[c]	Mutant	V441	interactions	 with	 the	 residue	 environment.	 Hydrogen	 bonding,	 hydrophobic	 and	 carbonyl	interactions	are	depicted.			Figure	4:	[a]	Interatomic	interactions	of	S437	(green)	with	the	residue	environment	in	the	wild-type	complex.	Hydrogen	bonding	interactions	with	S434,	G432	and	R173	(black	dashed	lines)	were	depicted.	[b]	Mutant	L437	with	hydrogen	bonding	and	hydrophobic	interactions	with	the	surrounding	residues.			Figure	 5:	 [a]	 Interactions	 of	 H476	 with	 the	 residue	 environment	 in	 the	 wild-type	 complex	include	hydrogen	bonds	 ((black	dashed	 lines),	 hydrophobic	 interactions	(green	dashed	 lines),	ionic	 interactions	 (yellow	 dashed	 lines),	 donor-p	 interactions	 (blue	 dashed	 lines),	 carbon-p	interactions	(grey	dashed	lines).	[b]	Mutant	R476	interactions	with	the	residue	environment.			Figure	6:	[a-d]	Difference	graphs	indicating	distortion	in	RMSD	(in	Å)	for	each	normal	mode	in	the	wild-type	and	in	each	of	the	mutant	models.		
